As a global healthcare provider, Novo Nordisk's key contribution is to discover and develop innovative medicines. Chief Science Officer Mads Krogsgaard Thomsen explains how we "innovate to improve the lives of people living with diabetes and other serious chronic diseases worldwide".
For many years we have worked on a scientific challenge: finding a way to deliver biological medicines in tablets rather than via injection. A recently published study in Science shows our progress, also explained in this film. The study is the result of a research collaboration with MIT, working to develop novel devices for oral administration of macro molecules.
We are looking to work with external partners that have complementary expertise to our own, both across our therapy areas and within each step of the pharmaceutical value chain.
Novo Nordisk's research and development facilities in Denmark, USA, UK, India and China form a global network that covers the entire pharmaceutical value chain across our therapy areas.